Skip to main content

Tekla Life Sciences Investors Declares Distribution

On February 15, 2022, Tekla Life Sciences Investors declared a distribution of $0.39 per share. The record date for the distribution is February 25, 2022 and the payable date is March 31, 2022. The Fund will trade ex-distribution on February 24, 2022.

This distribution will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder. The shares will be valued at the lower of the net asset value or market price on the pricing date, March 23, 2022. Fractional shares will generally be settled in cash, except for registered shareholders with book entry accounts at the transfer agent who will have whole and fractional shares added to their account.

Shareholders may request to be paid in cash instead of shares by responding to the bank, brokerage or nominee who holds the shares if the shares are in “street name” or by filling out an election card received from Computershare Investor Services shortly after the record date if the shares are in registered form. The bank, brokerage or nominee who holds the shares must advise the Depository Trust Company ("DTC") as to their full and fractional share requirements by March 22, 2022. Written notification for the election of cash instead of stock by registered shareholders must be received by Computershare Investor Services prior to March 22, 2022.

Tekla Life Sciences Investors (NYSE: HQL) is a closed-end fund that invests in public and private companies in the life sciences industry. Tekla Capital Management LLC, based in Boston, serves as Investment Adviser to the Fund. Shares of the Fund can be purchased on the New York Stock Exchange through any securities broker.

For additional information, please consult www.teklacap.com or call 877-855-3434

Contacts

For additional information, please consult www.teklacap.com or call 877-855-3434

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.